Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GC 3107A

Next Previous
Drug Profile

GC 3107A

Alternative Names: BCG vaccine - GC Biopharma; BCG vaccine - Green Cross; GC 3107; GC-3107A

Latest Information Update: 03 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer GC Biopharma
  • Class Antituberculars; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Tuberculosis

Most Recent Events

  • 31 Dec 2024 Preregistration for Tuberculosis (Prevention) in South Korea (Intradermal), before December 2024
  • 06 Sep 2022 Green Cross Corporation completes a phase III clinical trials in Tuberculosis (In infants, Prevention) in South Korea (Intradermal, Injection) (NCT03947138)
  • 29 Mar 2022 GC Pharma is now called GC Biopharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top